Bristol-Myers Squibb Shares Lose Ground in After-Hours Market
24 Juli 2019 - 11:45PM
Dow Jones News
By Stephen Nakrosis
Shares of pharmaceutical company Bristol-Myers Squibb Co. (BMY)
are falling in Wednesday's late trading session after the company
said a trial evaluating Opdivo plus chemotherapy in certain cancer
patients didn't meet its pre-specified primary endpoint.
At 5:04 p.m. EDT, Bristol-Myers Squibb shares had lost 4.7% to
trade at $41.20. After-hours volume topped 357,000 shares.
The company's shares closed the day's regular trading session
with a 0.42% gain at $43.23.
After the bell, the company said Part 1a of the Phase 3
CheckMate -227 trial evaluating Opdivo, or nivolumab, with low-dose
Yervoy, or ipilimumab, in certain cancer patients met the
co-primary endpoint of overall survival.
Part 2 of the CheckMate -227 trial, evaluating Opdivo plus
chemotherapy, didn't meet the pre-specified primary endpoint.
The company also said the time for its second-quarter earnings
call has been rescheduled to 8:30 a.m. EDT on July 25.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
July 24, 2019 17:30 ET (21:30 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
Von Mär 2023 bis Mär 2024